Bernard,
Got any thoughts on TLRK, GZMO, & BTRN from a TA perspective? All of these touched lows on better than average volume today. Climaxes, or more downside due? TLRK, in particular, has a large short position, probably because few think T67 will do much in the indications in which it is being tested. But the rest of the pipe looks good, and it has some cash. GZMO possibly down on no SAGE deals and leaked bad ASCO results (guessing with the rest of us peons on the latter). BTRN will probably need to finance, and MEDI is slow and won't take Rick's suggestion of testing 507 at low doses. All of this is history, so the TA future is . . . ?
BDAL also near lows with a large short position. Management has been hitting targets and recently declared good visibility for the next couple of quarters, so the only fundamental reason for the attack would be a belated focus on valuation, which is actually looking pretty reasonable in the $8 range.
Cheers, Tuck |
